immatics biotechnologies GmbH Market Cap ($5.77)
Market Cap & Net Worth: immatics biotechnologies GmbH (IMTXW)
immatics biotechnologies GmbH market cap. immatics biotechnologies GmbH (NASDAQ:IMTXW) has a market capitalization of $5.77 ($5.77) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #32102 globally and #6500 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying immatics biotechnologies GmbH's stock price $0.00 by its total outstanding shares 9617 (9.62K). Also see immatics biotechnologies GmbH operating cash flow efficiency for how efficiently the company converts equity into cash flow.
immatics biotechnologies GmbH Market Cap History (2020–2025)
immatics biotechnologies GmbH market cap history from 2020 to 2025. Data shows change from $27.70K to $5.77 (-83.89% CAGR). Check IMTXW share price today for real-time trading data and today's change.
immatics biotechnologies GmbH Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how immatics biotechnologies GmbH's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore IMTXW shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
immatics biotechnologies GmbH's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
immatics biotechnologies GmbH's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $27.70K | $31.25 Million | -$229.35 Million | 0.00x | N/A |
| 2021 | $42.22K | $34.76 Million | -$95.06 Million | 0.00x | N/A |
| 2022 | $24.14K | $172.83 Million | $37.51 Million | 0.00x | 0.00x |
| 2023 | $28.08K | $54.00 Million | -$96.99 Million | 0.00x | N/A |
| 2024 | $2.42K | $155.84 Million | $15.22 Million | 0.00x | 0.00x |
Competitor Companies of IMTXW by Market Capitalization
Companies near immatics biotechnologies GmbH in the global market cap rankings as of November 4, 2026. Also see how large is immatics biotechnologies GmbH's balance sheet for a full breakdown of the balance sheet.
Key companies related to immatics biotechnologies GmbH by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of immatics biotechnologies GmbH (2020–2025)
Market capitalization of immatics biotechnologies GmbH from 2020 to today. Between 2020 and today, immatics biotechnologies GmbH's market cap moved from $27.70K to $ 5.77, with a yearly change of -83.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $5.77 | -99.76% |
| 2024 | $2.42K | -91.39% |
| 2023 | $28.08K | +16.33% |
| 2022 | $24.14K | -42.82% |
| 2021 | $42.22K | +52.43% |
| 2020 | $27.70K | -- |
End of Day Market Cap According to Different Sources
On Jun 29th, 2026 the market cap of immatics biotechnologies GmbH was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.77 USD |
| MoneyControl | $5.77 USD |
| MarketWatch | $5.77 USD |
| marketcap.company | $5.77 USD |
| Reuters | $5.77 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapie… Read more